Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 10/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.50 |
| ▸ | METAP2 | P50579 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | HK1 | P19367 | 1/20 | 0.43 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | NEK2 | P51955 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29539829 | 1.00 | KEAP1 (0.50) | KEAP1NFE2L2METAP2MCL1HK1 | |
| SCHEMBL22922455 | 0.93 | KMT2A (0.47) | KEAP1NFE2L2METAP2MCL1HK1 | |
| SCHEMBL29539804 | 0.93 | KMT2A (0.47) | KEAP1NFE2L2METAP2MCL1HK1 | |
| SCHEMBL29539744 | 0.92 | KEAP1 (0.51) | KEAP1NFE2L2MCL1HK1HKDC1 | |
| SCHEMBL26356913 | 0.92 | KEAP1 (0.51) | KEAP1NFE2L2MCL1HK1HKDC1 | |
| SCHEMBL25057682 | 0.91 | KEAP1 (0.48) | KEAP1NFE2L2METAP2HKDC1CHEK1 | |
| SCHEMBL29539625 | 0.91 | KEAP1 (0.48) | KEAP1NFE2L2MCL1HKDC1KMT2A | |
| SCHEMBL29539562 | 0.91 | HKDC1 (0.47) | KEAP1NFE2L2MCL1HKDC1KMT2A | |
| SCHEMBL24299708 | 0.91 | HKDC1 (0.47) | KEAP1NFE2L2MCL1HKDC1KMT2A | |
| SCHEMBL26356935 | 0.91 | KEAP1 (0.48) | KEAP1NFE2L2MCL1HKDC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773057-B2 | Naphthalenesulfonamide compound, preparation method, and application | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| WO-2021012721-A1 | NAPHTHALENESULFONAMIDE COMPOUND, PREPARATION METHOD, AND APPLICATION | 中国药科大学 | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773057-B2 | Naphthalenesulfonamide compound, preparation method, and application | NFE2L2, KEAP1, NFE2 | KEAP1 2/4885NFE2L2 1/4885METAP2 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.